Oslo June 1[th], 2021 - Navamedic ASA ("Navamedic", OSE: NAVA) announces the
launch of new products in the Nordics.

Medical Nutrition is a strategically important area for Navamedic and to further
strengthen our presence, we have now launched three new products in this
category. The first to be launched is Glycosade Lemon for the dietary treatment
of Glycogen Storage Disease (GSD), an inborn error of metabolism. The other two,
K.Flo and K.Yo, are both used for the dietary management of drug-resistant
epilepsy or other conditions for which a ketogenic diet is indicated.

"We are proud to announce that the addition of these new products to the
existing portfolio will enhance our strategy of delivering a complete range of
products for patients with metabolic disorders or drug-resistant epilepsy. This
will give patients who are on a very strict dietary regimens an increased choice
of options which will make the adherence to dietary treatment easier."  says
Fredrik Karlsson, KAM Medical Nutrition of Navamedic.

Navamedic has products that combine the best of cutting-edge research with the
lifestyle demands of modern living. By launching new products to meet complex
dietary treatments, Navamedic will continue to offer new product lines
throughout the year, always with the patient at the core.

The Medical Nutrition business segment is based on the sale of products for the
treatment of inborn errors of metabolism (IEM). Within Medical Nutrition,
Navamedic is a Nordic distributor of products purchased from the UK based
company Vitaflo International ltd, a subsidiary of Nestlé. Navamedic's vendor
Vitaflo has more than 30 years of experience in producing specialist nutritional
products for Inborn Errors of Metabolism (IEM).

For more information, please contact:
Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA, +46
70 257 99 71 alexander.lidmejer@navamedic.com

About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com